parabolic2020
2 days ago
The TRUTH about what TXTM really is:
TXTM has developed a unique but entirely standards-compliant business model that integrates agricultural science, forward-looking valuation, proprietary extraction technology, and asset-backed corporate growth. It all begins with a validated seed multiplication contract that defines not just supply, but repeatable asset creation,allowing TXTM to book genetically stabilized, winterized, pure-strain genus sativa hemp seeds as biological assets under internationally recognized standards.
These seeds are exceptional in both form and function. Reported to yield plants between 9 to 12 feet tall and engineered with genetic traits that improve resilience, cannabinoid density, and long-term viability, they stand apart from traditional agricultural inventory. Very few suppliers in the global market can produce such a pure strain at scale, which makes these seeds fundamentally non-comparable to open-market hemp seeds. And that distinction matters, because TXTM is not assigning value based on market sales. Instead, its approach is rooted in IAS 41 Agriculture and supported by IFRS 13 and ASC 820 fair value measurement principles, which allow external, independent evaluators to assign value based on the seeds’ inherent biological and commercial potential, not based on what someone else might pay for them in a retail setting.
This is a key part of the company’s strategy. These seeds are not being sold to the public. They are retained internally, forming the basis of TXTM’s seed multiplication contract refrencing production cycles, planted and rotated using a FIFO method to preserve viability and consistency. And because of their dual value as living biological assets and as extractable materials, the seeds remain viable even past germination. Using its patented extraction technology, TXTM can recover cannabinoids from seeds or plants and use the resulting oils in various end products, including nutraceuticals and biofuels, as part of its vertically integrated ecosystem.
This asset model does more than just maintain value, it scales it. With each grow cycle, asset volume increases. With each extraction cycle, product inventory grows. And all of it can be measured, verified, and booked under IFRS and GAAP. External valuation firms play a critical role here, as they can establish the value of the seed inventory not by referencing external sales, but by considering unique, observable inputs like yield history, genetic quality, extractable content, and expected future replication. These valuations are defensible under both U.S. and international accounting standards, and they give TXTM the ability to book forward-looking asset value with full transparency and auditability.
As a result, TXTM has grown its balance sheet significantly, rising from $15 million to over $255 million in booked assets within just two years, without relying on dilution, debt, or speculative licensing. But now, having successfully established its replicating asset base and proprietary processing infrastructure, the company is positioned to take the next strategic step.
TXTM is not a traditional grower nor dies it engage in actual farming, it is a holding company with a targeted acquisition and asset deployment subsidiary. These biological assets and the value they hold are not just sitting on the books, they are being positioned for use as collateral, to support tokenization, structured finance, and leveraged acquisitions. This enables TXTM to begin pulling in other companies, whether revenue-generating entities, IP holders, or production facilities—under its corporate umbrella, without needing to draw from cash reserves or take on traditional debt.
This is the blueprint now unfolding: TXTM uses its internally generated, independently valued biological assets to finance strategic expansion. The seeds fuel the valuation. The valuation fuels the leverage. The leverage fuels the acquisitions. And through its dedicated acquisition arm, TXTM can absorb and support companies that align with its long-term growth model—building out a portfolio of assets and entities that collectively enhance the value of the holding company.
What’s happening here is not a speculative promise. It is a measurable, standards-driven transformation of a biological asset platform into a vertically integrated, financially self-sufficient acquisition engine. TXTM is executing a scalable strategy where replicating, income-capable assets form the foundation of a new kind of holding company, one that expands not through dilution, but through asset-driven leverage. And it is now in motion. IMO this strategy will be as aggressive as the growth on it's balance sheet has been. The current assat inventory stands at 600 million seeds, with an impending harvest that, taking into account the accumulation trend of the assets could propel total seed assets far in excess of 1 billion. When proper valuation is set by independent valuators as have been communicated,and the PCAOB audits are fully complete, there will be no doubt whT initial sharholders have seen coming all along. When the world realizes what is happening here, the stock will begin to reflect what this really is. I'll say it again. It was all a lie, or all the truth.
These are my opinions.
GLTU
parabolic2020
2 days ago
Hmmm. Funny you say that. Now that the company is fully trading again, maybe its timenfir a trip back down memory lane to show what this company really is. Because, if it wasn't all a lie, then it time to face the uncomfortable truth that everything WAS true. What that means for Investors may seem like a fairy tale to some, but the numbers don't lie, starting a a 1/4 billion virtually debt free assets. This is as real as it gets and it won't take a reverse split EVER. Remember, the company said that as well. This is a massive money printing aquistion machine that has established it business model and collateral asset base which is the first step in an aquistion model. You need capital or a way to leverage assets to perform aquistions. The Multiplication Program and our balance sheet shows that has been verified.Next step has multiple paths. Tokenization of those assets, direct collateralized loans leveraging said assets using lines of credit and other tools, as our assets stay on the books and NEVER sold. Meanwhile developing our tech to extract cannabinoids form both plants and seeds as evidenced by Dr.J's numerous posts. Remember also this tech is not limited to cannabinoids or hemp. You tie it all together and maybe you begin to see what the world is just starting to figure out, and we have known all along.This is a massive asset replicating aquistion model, capable of 100 million dollar aquistions at present, and very likely billions in the near future.Enjoy the ride. I know I will.
GLTU